Trial-Results center  
Clinical trial results database Feedback    Home


Related trials

ZEST AMI (vs SES), 2009 - zotarolimus ES vs sirolimus ES

TRIANA, 2009 - primary ballon angioplasty vs tenecteplase

NORDISTEMI, 2009 - thrombolysis + angioplasty vs immediate thrombolysis

Juwana, 2009 - sirolimus ES vs paclitaxel ES

ZEST AMI (vs PES), 2009 - zotarolimus ES vs paclitaxel ES

PASEO, 2009 - drug ES vs bare-metal stent

CARESS, 2008 - thrombolysis + angioplasty vs immediate thrombolysis

HORIZONS-AMI Stent, 2008 - paclitaxel ES vs bare-metal stent

MISSION, 2008 - sirolimus ES vs bare-metal stent

DEDICATION, 2008 - drug ES vs bare-metal stent

Díaz de la Llera, 2007 - sirolimus ES vs bare-metal stent

SESAMI, 2007 - sirolimus ES vs bare-metal stent

TYPHOON, 2006 - sirolimus ES vs bare-metal stent

PROSIT, 2006 - sirolimus ES vs paclitaxel ES

HAAMU-STENT, 2006 - paclitaxel ES vs bare-metal stent

PASSION, 2006 - paclitaxel ES vs bare-metal stent

WEST, 2006 - systematic PCI (+stent) vs no systematic PCI

CAPITAL AMI, 2005 - thrombolysis + angioplasty vs immediate thrombolysis

Di Lorenzo et al., 2005 - sirolimus ES vs paclitaxel ES

ZWOLLE 6, 2005 - primary stenting vs ballon angioplasty

CAPITAL AMI, 2005 - systematic PCI (+stent) vs no systematic PCI

senior PAMI, 2005 - primary PCI vs thrombolytic therapy

STOPAMI 3, 2004 - primary stenting vs ballon angioplasty

GRACIA-1, 2004 - systematic PCI (+stent) vs no systematic PCI

MERLIN (Sutton), 2004 - immediate systematic ballon angioplastyte vs no immediate angioplasty



See also:

  • All acute myocardial infarction clinical trials
  • All clinical trials of myocardial revascularization
  • All clinical trials of APSAC
    		•  

    German Multicenter Trial study, 1988

    Treatments

    Studied treatment APSAC 30 unités en IV en 5 min, puis héparine en IV (17 U/kg/h) 4 h après l'injection d'APSAC
    Control treatment Héparine 5000 U en bolus en IV, puis 17 U/kg/h
    Concomittant treatment Méthylprednisolone 100 mg en IV avant traitement, héparine ou (phenprocoumone) poursuivie jusqu'au cathétérisme cardiaque; ajustement des doses en fonction du TCK (1.5 à 2 fois le témoin); Traitements actifs sur le plan cardiaque adaptés selon les besoins de chaque patient

    Patients

    Patients Hommes et femmes, < 70 ans
    Inclusion criteria IDM < 4 h; sus-décalage ST > ou = 1 mm dans au moins 1 dérivation standard, ou ST > ou = 2 mm dans au moins 1 dérivation précordiale, non annulé par nitrés ou Ca-bloqueurs
    Exclusion criteria Contre-indication au traitement thrombolytique

    Method and design

    Randomized effectives 162 / 151 (studied vs. control)
    Design Parallel groups
    Follow-up duration 28 jours
    Lost to follow-up ND
    Primary endpoint in hospital death
    Withdrawals (T1/T0) ND /


    Results

    Endpoint Studied treat.
    n/N     Control treat.
    n/N     Graph RR [95% CI]

    short term death

    9 / 162
         19 / 151
         0,44 [0,21;0,95]

    Major bleeding

    10 / 162
         5 / 151
         classic 1,86 [0,65;5,33]     0 2 1.0

    Relative risks
    Endpoint Events (%) Relative Risk 95% CI Endpoint definition
    in the trial    		 Ref
    Studied treat. Control treat.
    short term death 9 / 162 (5,6%) 19 / 151 (12,6%) 0,44 [0,21;0,95]    
    Major bleeding 10 / 162 (6,2%) 5 / 151 (3,3%) 1,86 [0,65;5,33]    
    The primary endpoint (if exists) appears in blod characters
    Reference(s) used for data extraction:
  • 0:

    • Endpoint studied treat. control treat. mean diff

    Absolute risk reduction
    Endpoint Events rate Absolute risk
    reduction (ARR)
    Studied treat. Control treat.
    short term death 5,56% 12,58% -70,3‰
    Major bleeding 6,17% 3,31% 2,9%


    Reference(s)

    Trials register # NA

    (c) 2004-2010 TrialResults-center - All Rights Reserved

    Tweet this  |  notify a friend